Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3564060 | 1.00 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL3198780 | 1.00 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL2181309 | 1.00 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4527860 | 1.00 | GAA (0.43) | GAANFKB1NFKB2RELAEPHX2 | |
| Hydrochloric Acid SCHEMBL30478389 | 0.98 | GAA (0.42) | GAANFKB1NFKB2RELAEPHX2 | |
| Formic Acid SCHEMBL9046870 | 0.94 | GAA (0.39) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL6167830 | 0.93 | GAA (0.41) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL6167832 | 0.93 | GAA (0.41) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL5024706 | 0.91 | GAA (0.46) | GAANFKB1NFKB2RELAEPHX2 | |
| SCHEMBL4643757 | 0.91 | GAA (0.46) | GAANFKB1NFKB2RELAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0443498-A1 | Isoindoline derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-28 | — | — | EP | claimed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| CN-118894840-A | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-110944990-B | TLR7/8 antagonists and uses thereof | 默克专利股份公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-4248968-A2 | TLR7/8 ANTAGONISTS AND USES THEREOF | Merck Patent GmbH (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-3655401-B1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023083283-A1 | DRUG COMBINATION FOR TREATING TUMOR, AND APPLICATION THEREOF | 先声药业有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-26 | — | — | US | disclosed |
| US-4980470-A | 8-alkoxyquinolonecarboxylic acid and salts thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-12-25 | — | — | US | disclosed |
| EP-0393400-A1 | Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0208210-B1 | PYRIDONECARBOXYLIC ACID DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4894458-A | BACTERICIDES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1990-01-16 | — | — | US | disclosed |
| EP-0341493-A2 | Optically active pyridonecarboxylic acid derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1989-11-15 | — | — | EP | disclosed |
| US-4855292-A | ANTIMICROBIAL AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-08-08 | — | — | US | disclosed |
| US-4753953-A | Pyridonecarboxylic acid derivatives and antibacterial pharmaceutical compositions thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0235762-A1 | 8-Position substituted quinolone-carboxylic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| EP-0230295-A2 | 8-alkoxyquinolonecarboxylic acid and salts thereof excellent in the selective toxicity and process of preparing the same | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-07-29 | — | — | EP | disclosed |
| EP-0208210-A1 | Pyridonecarboxylic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | GAA 1009/4885NFKB1 1349/4885NFKB2 878/4885 |
| US-20200369648-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | GAA 874/4885NFKB1 497/4885NFKB2 273/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | GAA 2631/4885NFKB1 3064/4885NFKB2 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.